3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Buy
51
BMY Quote, Financials, Valuation and Earnings
Last price:
$59.33
Seasonality move
:
3.14%
Day range:
$59.37 - $61.64
52-week range:
$39.35 - $63.33
Dividend yield:
3.97%
P/E ratio:
--
P/S ratio:
2.56x
P/B ratio:
7.58x
Volume:
11.6M
Avg. volume:
12.4M
1-year change:
12.47%
Market cap:
$123.8B
Revenue:
$48.3B
EPS (TTM):
-$4.42
Analysts' Opinion
-
Consensus RatingBristol-Myers Squibb has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 18 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $61.24, Bristol-Myers Squibb has an estimated upside of 0.42% from its current price of $60.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $37.00 representing 100% downside risk from its current price of $60.99.
Fair Value
-
According to the consensus of 22 analysts, Bristol-Myers Squibb has 0.42% upside to fair value with a price target of $61.24 per share.
BMY vs. S&P 500
-
Over the past 5 trading days, Bristol-Myers Squibb has overperformed the S&P 500 by 1.69% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bristol-Myers Squibb does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bristol-Myers Squibb has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Bristol-Myers Squibb reported revenues of $12.3B.
Earnings Growth
-
Bristol-Myers Squibb earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Bristol-Myers Squibb reported earnings per share of $0.04.
Enterprise value:
162.6B
EV / Invested capital:
--
Price / LTM sales:
2.56x
EV / EBIT:
--
EV / Revenue:
3.37x
PEG ratio (5yr expected):
--
EV / Free cash flow:
11.66x
Price / Operating cash flow:
8.87x
Enterprise value / EBITDA:
51.33x
Gross Profit (TTM):
$34.3B
Return On Assets:
-9.42%
Net Income Margin (TTM):
-18.53%
Return On Equity:
-46.27%
Return On Invested Capital:
-13.01%
Operating Margin:
4.13%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $46.2B | $45B | $48.3B | $11.5B | $12.3B | |
| Gross Profit | $36B | $34.3B | $34.3B | $8.7B | $7.5B | |
| Operating Income | $9.1B | $8.2B | $5.9B | $1.9B | $510M | |
| EBITDA | $19.2B | $19.4B | $3.2B | $4.5B | $2.6B | |
| Diluted EPS | $2.95 | $3.86 | -$4.42 | $0.87 | $0.04 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $30.2B | $33.3B | $27.3B | $31.8B | $29.8B | |
| Total Assets | $118.5B | $109.3B | $96.8B | $95.2B | $92.6B | |
| Current Liabilities | $19.1B | $21.9B | $21.9B | $22.3B | $23.8B | |
| Total Liabilities | $80.6B | $73.3B | $65.7B | $65.7B | $76.2B | |
| Total Equity | $37.9B | $36B | $31.1B | $29.5B | $16.4B | |
| Total Debt | $50.7B | $44.6B | $39.3B | $39.8B | $49.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $13.1B | $13.9B | $15.2B | $4.3B | $4.4B | |
| Cash From Investing | -$1.1B | -$2.3B | -$21.4B | -$1.3B | -$196M | |
| Cash From Financing | -$17B | -$9.4B | $5.1B | $967M | -$1.6B | |
| Free Cash Flow | $11.9B | $12.7B | $13.9B | $3.9B | $4.1B | |
BMY
Sector
Market Cap
$123.8B
$37M
Price % of 52-Week High
96.31%
43.14%
Dividend Yield
3.97%
0%
Shareholder Yield
2.14%
-1.03%
1-Year Price Total Return
12.47%
-43.58%
Beta (5-Year)
0.408
0.746
Dividend yield:
3.97%
Annualized payout:
$2.40
Payout ratio:
-54.35%
Growth streak:
3 years
Technicals
8-day SMA
Buy
Level
$60.11
200-day SMA
Buy
Level
$52.64
Bollinger Bands (100)
Buy
Level
56.05 - 59.71
Chaikin Money Flow
Buy
Level
722.3M
20-day SMA
Buy
Level
$60.09
Relative Strength Index (RSI14)
Buy
Level
57.32
ADX Line
Buy
Level
15.82
Williams %R
Sell
Level
-19.0616
50-day SMA
Buy
Level
$58.51
MACD (12, 26)
Buy
Level
0.51
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
607.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.4991)
Sell
CA Score
(Annual)
Level (-1.7489)
Buy
Beneish M-Score
(Annual)
Level (-3.72)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-0.0559)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Stock Forecast FAQ
In the current month, BMY has received 3 Buy ratings 18 Hold ratings, and 1 Sell ratings. The BMY average analyst price target in the past 3 months is $61.24.
-
Where Will Bristol-Myers Squibb Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bristol-Myers Squibb share price will rise to $61.24 per share over the next 12 months.
-
What Do Analysts Say About Bristol-Myers Squibb?
Analysts are divided on their view about Bristol-Myers Squibb share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bristol-Myers Squibb is a Sell and believe this share price will drop from its current level to $37.00.
-
What Is Bristol-Myers Squibb's Price Target?
The price target for Bristol-Myers Squibb over the next 1-year time period is forecast to be $61.24 according to 22 Wall Street analysts, 3 of them rate the stock a Buy, 1 rates the stock a Sell, and 18 analysts rate the stock a Hold.
-
Is BMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bristol-Myers Squibb is a Hold. 18 of 22 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BMY?
You can purchase shares of Bristol-Myers Squibb via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bristol-Myers Squibb shares.
-
What Is The Bristol-Myers Squibb Share Price Today?
Bristol-Myers Squibb was last trading at $59.33 per share. This represents the most recent stock quote for Bristol-Myers Squibb. Yesterday, Bristol-Myers Squibb closed at $60.99 per share.
-
How To Buy Bristol-Myers Squibb Stock Online?
In order to purchase Bristol-Myers Squibb stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is down 16.86% over the past day.
Sell
16
PCVX alert for Apr 1
Vaxcyte [PCVX] is down 11.04% over the past day.
Buy
74
COOP alert for Apr 1
Mr. Cooper Group [COOP] is up 4.12% over the past day.
